Mikhail Krasavin


Feb 2016 elected Professor of the Russian Academy of Sciences (the RAS Profesor) RU


11/2011 Defended (24.05.2011) a DSc (Habilitation) Dissertation «New Synthetic Strategies Involving Isocyanide-Based Multicomponent Reactions». The respective degree in Organic Chemistry was conferred by the Higher Attestation Committee of the Russian Federation on 18.11.2011
12/2006 Defended (06.12.2006) a PhD Dissertation «Design, Synthesis and Biological Activity of 1,2,4-Trioxane Analogs of Artemisinin» in Organic Chemistry at the Gubkin Gas & Oil University of Russia (Moscow)
05/1999 Master of Arts in Organic/Medicinal Chemistry (under Prof Gary H. Posner) from The Johns Hopkins University (Baltimore, MD)
06/1997 Visiting Diploma student at Organic Chemistry Dept, Lund University (Sweden)
01/1997 Completed undergraduate chemistry training with concentration in Physical Organic Chemistry (St. Petersburg State University, Russia)
May 19-23rd, 2003 Pharmaceutical Industry Short Course in Pharmacology (U Wisconsin, Madison)
01-10/2009 Advanced training course in Natural Science Teaching Methodology (The Ushinsky State Pedagogical University, Yaroslavl, Russia)


2014 – present Professor of Organic Chemistry, St. Petersburg State University (Russia)
  • Teaching and supervision of an independent research group. Multiple collaborations in the field of medicinal chemistry and drug discovery across the Globe.
  • Recipient of a 2014-2018 Russian Scientific Fund institutional grant (along with four other recipients) «Translational biomedicine at SPbSU», aimed at establishing a chemical pharmacology laboratory within the University.
2011 – 2013 Group Leader and Institute Member, Eskitis Institute for Drug Discovery, Griffith University (Brisbane, QLD, Australia)
  • Ran an independent research group in synthetic and medicinal chemistry (2 PhD students, 1 Master student, 1 postdoc)
  • Attracted external grant funding (AU$115,000 from Griffith University in 2012-2013, AU$395,000 from Australian Research Council in 2013)
  • Served as the Chairman of the Queensland Compound Library Management Committee, the only Australian resource providing compounds for biological screening
  • Liaised closely with the State and Federal governments on QCL funding
  • Attracted AU$2.5M in Federal funding for expanding the QCL’s infrastructure
  • Selected and purchased a diverse library of 34,000 new drug-like compounds from 11 major compound vendors worldwide
  • Built effective collaborations with research groups in U California, Aristotle University in Greece, U Alberta in Canada, U Sydney, U Melbourne, U Western Australia aimed at biological profiling of the new compounds designed and synthesized in my group
  • Building industry collaborations (Eli Lilly and Co., Merck KGaA) in the area of Open Innovation in drug discovery
2007 – 2011 Head of Medicinal Chemistry, Chemical Diversity Research Institute (Khimki, Moscow)
  • Ran project groups of 4-20 researchers in preclinical drug discovery research in such therapeutic areas as oncology, metabolic disease, central nervous system disease for such key pharma and biotech clients as Abbott Laboratories, Solvay Pharmaceuticals, Nerviano Medical Sciences
  • Identified and optimized (with respect to the target biological activity, ADMET profile and off-target profile over 20 lead series, some of which reached a clinical candidate status
  • Advanced one chemical series (see patents with Nerviano Medical Sciences) to the clinicalcandidate status in oncology
  • Extensive off-site meetings to develop new proposals, project structure, evaluate project costs and develop milestone criteria
  • Maintained regular detailed and time-bound reporting on the projects, met with the clients face-to-face to discuss research progress and develop solutions to emerging hurdles
  • Analyzed biological data and made decisions on advancement or discontinuation of particular biologically active chemical series
  • Interacted closely with cross-functional teams including compound management, logistics, computational chemistry, high-throughput screening, in vitro and in vivo pharmacology
  • Outsourced parts of project work to academic and industry partners
2007 Postdoctoral fellow, Dept of Chemistry, McGill University (Montreal, Quebec)
  • Short-term research visit to Ass. Prof. Marcus Lindström's group to work on enantioselective catalysis in water
  • Joint publication in Eur. J. Org. Chem.
2004 – 2007 Associate Director for Custom Chemistry, Chemical Diversity Research Institute (Khimki, Moscow)
  • Built a custom synthesis program from scratch to accommodate strong partnering demand from key pharma and biotechnology clients
  • Ran project teams of 5-35 chemists
  • Successfully closed >$10M in synthesis contracts for such clients as Eli Lilly and Co., Merck KGaA, Sanofi Aventis, GSK, Takeda Pharmaceutical Co., Bayer-Schering and others
  • Traveled extensively for client meetings to develop new proposals, project structure, evaluate project costs and develop milestone criteria
  • Maintained regular detailed and time-bound reporting on the projects, met with the clients face-to-face to discuss research progress and develop solutions to emerging hurdles
2002 – 2003 Senior Research Associate, Medicinal Chemistry, Abbott Bioresearch Center (Worcester, MA)
2000 – 2001 Senior Research Associate, Medicinal Chemistry, Millennium Pharmaceuticals, Inc. (Cambridge, MA)
  • Conducted laboratory research in synthetic organic and medicinal chemistry to support preclinical discovery programs in immunology and oncology (targets – kinases, GPCRs)
  • Wrote regular research reports, submitted compounds for biological profiling, interacted with the biology and crystallography teams to define path for further optimization of active chemical series
1997 – 1999 Graduate research associate and Teaching assistant, The Johns Hopkins University (Baltimore, MD)
  • Led section seminars in organic chemistry for sophomore and junior chemistry and pre-med students
  • Graded exams
  • Laboratory research to synthesize and study biologically active analogs of an antimalarial natural product
  • Responsible for compounds' testing at the JHU School of Medicine














H-index — 26 (Web of Science)

H-index — 30 (Scopus)

H-index — 33 (Google Scholar)

▲ Back to Top